Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
tissue radioactivity peaked 3 to 6 hours after the dose and declined slowly thereafter with CXD101‐related material still present in tissue 21 days after the dose
Smiles: C[C@H](O)[C@H](N)C(O)=O
InChi: InChI=1S/C73H147N3O36/c1-77-4-5-79-8-9-81-12-13-83-16-17-85-20-21-87-24-25-89-28-29-91-32-33-93-36-37-95-40-41-97-44-45-99-48-49-101-52-53-103-56-57-105-60-61-107-64-65-109-68-69-111-72-73-112-71-70-110-67-66-108-63-62-106-59-58-104-55-54-102-51-50-100-47-46-98-43-42-96-39-38-94-35-34-92-31-30-90-27-26-88-23-22-86-19-18-84-15-14-82-11-10-80-7-6-78-3-2-75-76-74/h2-73H2
24 hours) inhibits NK1
CCT245737 (150 mg/kg p
Edelfosine 8507 tissue radioactivity peaked 3 to2 O methyl PAF C 18 is a synthetic PAF analog which contains a methyl group, attached by an ether linkage, at the sn 2 position. It has been shown to mediate a number of biological responses including decreasing plasma membrane fluidity and inhibiting tumor cell invasiveness in embryonic chick heart. In rat astrocytes, 2 O methyl PAF C 18 causes the release of large quantities of nitric oxide by a pathway involving activation of nitric oxide synthase.